-+ 0.00%
-+ 0.00%
-+ 0.00%

Lakewood-Amedex Faces Nasdaq Delisting Over Minimum Bid Price Violation

PUBT·11/16/2026 21:42:59
Listen to the news
Lakewood-Amedex Faces Nasdaq Delisting Over Minimum Bid Price Violation
  • Nasdaq notified Lakewood-Amedex Biotherapeutics on November 10, 2026, that its securities face delisting for violating the minimum bid price requirement.
  • Common stock closed below $1.00 for 30 consecutive business days from September 29 through November 9, 2026.
  • A 1-for-10 reverse stock split on June 22, 2026, makes the company ineligible for a compliance period.
  • Trading will be suspended November 19, 2026, unless a hearing is requested by November 17, 2026.
  • The company intends to request a hearing, staying suspension pending a decision, and present a compliance plan potentially including another reverse split.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-120724), on November 16, 2026, and is solely responsible for the information contained therein.